Shares of LifeStance Health Group, Inc. (NASDAQ:LFST – Get Rating) have been given an average rating of "Moderate Buy" by the six research firms that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $8.21.
Several research analysts recently weighed in on the stock. Jefferies Financial Group reaffirmed a "buy" rating and issued a $7.25 target price on shares of LifeStance Health Group in a report on Monday, November 7th. Cowen dropped their price objective on shares of LifeStance Health Group from $10.00 to $8.00 and set an "outperform" rating for the company in a report on Monday, November 14th. Cowen dropped their price objective on shares of LifeStance Health Group from $10.00 to $8.00 and set an "outperform" rating for the company in a report on Monday, November 14th. The Goldman Sachs Group dropped their price objective on shares of LifeStance Health Group from $9.00 to $8.00 and set a "neutral" rating for the company in a report on Tuesday, November 15th. Finally, Morgan Stanley raised shares of LifeStance Health Group from an "equal weight" rating to an "overweight" rating and set a $8.00 price objective for the company in a report on Friday, January 6th.
Get
LifeStance Health Group alerts:
LifeStance Health Group Trading Down 4.5 %
NASDAQ:LFST opened at $5.29 on Tuesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.25 and a quick ratio of 2.25. The firm has a market capitalization of $1.99 billion, a price-to-earnings ratio of -6.61 and a beta of 0.51. LifeStance Health Group has a one year low of $4.22 and a one year high of $11.25. The business has a fifty day moving average price of $5.06 and a 200-day moving average price of $6.39.
LifeStance Health Group (NASDAQ:LFST – Get Rating) last posted its quarterly earnings data on Tuesday, November 8th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.04. The firm had revenue of $217.56 million during the quarter, compared to analyst estimates of $219.69 million. LifeStance Health Group had a negative return on equity of 18.01% and a negative net
margin of 33.77%. Sell-side analysts forecast that LifeStance Health Group will post -0.6 EPS for the current year.
Insider Activity at LifeStance Health Group
In related news, insider Warren Gouk sold 15,106 shares of the stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $7.20, for a total value of $108,763.20. Following the sale, the insider now directly owns 5,967,991 shares of the company's stock, valued at approximately $42,969,535.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 16.59% of the stock is owned by insiders.
Institutional Trading of LifeStance Health Group
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in LifeStance Health Group by 13.5% in the 3rd quarter. Vanguard Group Inc. now owns 6,994,133 shares of the company's stock worth $46,301,000 after purchasing an additional 832,246 shares during the period. Stockbridge Partners LLC purchased a new position in shares of LifeStance Health Group during the first quarter worth approximately $53,529,000. BlackRock Inc. increased its position in shares of LifeStance Health Group by 21.7% during the third quarter. BlackRock Inc. now owns 5,146,718 shares of the company's stock worth $34,073,000 after acquiring an additional 915,997 shares during the period. Principal Financial Group Inc. increased its position in shares of LifeStance Health Group by 34.8% during the second quarter. Principal Financial Group Inc. now owns 3,367,625 shares of the company's stock worth $18,724,000 after acquiring an additional 868,946 shares during the period. Finally, State Street Corp increased its position in shares of LifeStance Health Group by 22.3% during the third quarter. State Street Corp now owns 1,402,221 shares of the company's stock worth $9,283,000 after acquiring an additional 256,009 shares during the period. 76.49% of the stock is owned by hedge funds and other institutional investors.
About LifeStance Health Group
(Get Rating)
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
See Also
- Get a free copy of the StockNews.com research report on LifeStance Health Group (LFST)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
